| Autor: |
Chernov AN; Institute of Experimental Medicine, Russian Academy of Medical Sciences, Saint-Petersburg, Russia., Alaverdian DA; MedicalGenetics, Department of Medical Biotechnologies, University of Siena, Siena, Italy.; MedBiotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy., Galimova ES; I. M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint-Petersburg, Russia., Renieri A; MedicalGenetics, Department of Medical Biotechnologies, University of Siena, Siena, Italy.; MedBiotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.; Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy., Frullanti E; MedicalGenetics, Department of Medical Biotechnologies, University of Siena, Siena, Italy.; MedBiotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy., Meloni I; MedicalGenetics, Department of Medical Biotechnologies, University of Siena, Siena, Italy.; MedBiotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy., Shamova OV; Institute of Experimental Medicine, Russian Academy of Medical Sciences, Saint-Petersburg, Russia. |
| Abstrakt: |
The most common and aggressive brain tumor in the adult population is glioblastoma (GBM). The lifespan of patients does not exceed 22 months. One of the reasons for the low effectiveness of GBM treatment is its radioresistance and chemoresistance. In the current review, we discuss the phenomenon of multidrug resistance of GBM in the context of the expression of ABC family transporter proteins and the mechanisms of proliferation, angiogenesis, and recurrence. We focused on the search of molecular targets among growth factors, receptors, signal transduction proteins, microRNAs, transcription factors, proto-oncogenes, tumor suppressor genes, and their single-nucleotide polymorphisms. |
